What Every Aesthetic Practitioner Needs to Know About GLP-1-Associated Facial Changes

Susan Oakes, Nurse Prescriber shares her clinical observations and treatment approach to the facial and skin changes she is seeing in patients experiencing rapid weight loss while using GLP-1 receptor agonists.

Introduction: From Diabetes Management to Weight Loss Medicine

Glucagon-like peptide-1 receptor agonists were originally developed for the management of type 2 diabetes mellitus, based on the incretin effect described in the mid-twentieth century.₁ GLP-1 is an endogenous gut hormone secreted in response to nutrient intake. It enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying and promotes satiety.₂

The first GLP-1 receptor agonist, exenatide, was licensed in 2005 for type 2 diabetes.₃ Since then, longer-acting agents such as liraglutide, semaglutide and tirzepatide have demonstrated not only effective glycaemic control but also substantial and sustained weight reduction.₄–₆ Large randomised controlled trials including the STEP and SURPASS programmes report mean weight loss ranging from 10 to 22 per cent of baseline body weight, depending on dose and duration.₅˒₆

In the United Kingdom, uptake for weight management has increased rapidly. Recent population data from Great Britain estimate that approximately 2.9 per cent of adults, equating to around 1.6 million people, reported using GLP-1 or GLP-1/GIP medications for weight loss within the past year.₇ This reflects a significant shift in obesity management within a relatively short time frame. As prescribing expands, aesthetic practitioners are increasingly encountering patients experiencing rapid pharmacologically mediated weight loss.

It is important to state clearly that the aesthetic changes we are observing are not adverse drug reactions in the traditional sense. They are physiological consequences of accelerated adipose and, in some cases, lean mass reduction. However, they are visible, emotionally impactful and increasingly driving aesthetic consultations.

---

What Patients Are Presenting With

Patients rarely attend and request “more filler.” Instead, their concerns are more nuanced. They tell me that they feel they look tired. They say their face appears flat. Some express that their lower face seems to have dropped. Many are pleased with their weight loss and describe feeling healthier and more confident in their bodies. Yet they are unsettled by what they see in the mirror.

In my clinic, three dominant patterns are emerging. These include facial volume loss, increased skin laxity and noticeable changes in skin quality. Each of these requires careful differentiation and a tailored treatment plan.

---

Facial Volume Loss: Deflation Rather Than Traditional Ageing

The most striking change is midface deflation. Rapid adipose reduction affects both superficial and deep fat compartments, particularly the deep medial cheek fat pad and lateral cheek structures.₈ Clinically, this presents as flattening of the anterior cheek projection, loss of the natural ogee curve and increased shadowing of the nasolabial region. As midface support diminishes, the lower third appears heavier, even when overall facial fat has reduced.

Evidence from body composition studies suggests that weight loss associated with GLP-1 receptor agonists includes a proportion of lean mass reduction.₆ Although most available data focus on truncal and limb musculature, it is reasonable to infer that global soft tissue support may also be affected. The face, therefore, does not simply lose fat; it may lose structural support.

Importantly, what we are seeing is often deflation rather than classical intrinsic ageing. The lower face may appear to droop, but this frequently represents the unmasking of pre-existing laxity following loss of midface projection. Recognising this distinction is essential, as it directly influences treatment planning.

---

Skin Laxity: The Pace of Weight Loss Matters

Skin remodelling does not occur at the same rate as fat loss. Collagen turnover is gradual, and rapid reductions in body weight can outpace dermal adaptation. This is particularly relevant in patients over the age of 35 and in those experiencing perimenopausal hormonal changes, where declining oestrogen levels further affect collagen integrity.

Clinically, I observe softened jawline definition, increased submental laxity, greater prominence of neck bands and crepiness in the lower face. Treating these changes purely with volumisation can create heaviness in an already lean facial frame. Differentiating between volume depletion and intrinsic laxity is therefore critical.

---

Changes in Skin Quality

Beyond structural change, skin quality is frequently affected. Patients describe dullness, dehydration and exaggeration of fine lines. Several factors may contribute, including reduced caloric and protein intake, micronutrient deficiencies, hormonal fluctuations and relative sarcopenia. The skin may appear thinner and less resilient, contributing to the perception of looking fatigued or unwell.

In many cases, this aspect is more distressing to patients than the actual volume loss. It affects how light reflects off the skin and how rested the individual appears.

---

Consultation Principles: Stabilise and Stage

Timing is one of the most important considerations. If a patient is actively losing weight, facial proportions are still evolving. I strongly favour allowing weight to stabilise before undertaking significant volumisation. Treating too early can result in chasing ongoing change and increases the risk of overcorrection.

My consultation process includes discussion of current weight trajectory, duration of GLP-1 therapy, nutritional intake, hormonal context and the patient’s motivation for treatment. The aim is not to recreate a pre-weight-loss face but to restore balance and harmony.

---

Treatment Strategies in Practice

Structural Dermal Filler

When addressing volume loss, I adopt a conservative structural approach using hyaluronic acid dermal filler placed in deeper planes. Restoring projection in the medial and lateral cheek and addressing temporal hollowing can re-establish support without creating excess fullness. Rather than chasing lines, I focus on rebuilding structure.

Staging treatment is key. Small volumes administered over multiple sessions allow for reassessment and integration. Lean faces do not tolerate excessive product, and subtle correction often achieves the most natural result.

Collagen Induction and Regenerative Therapies

In many patients, collagen stimulation is as important as volume restoration.

Medical microneedling stimulates neocollagenesis through controlled dermal injury and growth factor release. Over a course of treatments, improvements in dermal density and texture can be achieved without altering facial proportions. This is particularly effective in patients with mild laxity and thinning skin.

Polynucleotide treatments enhance fibroblast activity and support tissue repair, improving elasticity and hydration. In my experience, they are especially beneficial for addressing lower-face crepiness and generalised thinning.

Skin boosters can support hydration and improve fine lines, although they are adjunctive rather than primary structural treatments.

Biostimulation with Calcium Hydroxylapatite

Radiesse provides both immediate support and longer-term collagen stimulation. In carefully selected patients, diluted protocols can enhance tissue firmness and dermal quality. Precision and patient selection are essential, particularly in very lean faces.

Medical-Grade Skincare and Prescription Retinoids

Optimising skin physiology is foundational. Prescription tretinoin remains one of the most evidence-based topical agents for stimulating collagen production and improving dermal architecture.₉ Gradual introduction enhances dermal thickness and reduces fine lines over time.

Antioxidant support, barrier repair and daily broad-spectrum SPF are essential components of any regenerative plan. In some cases, collaboration with primary care for the investigation of iron deficiency or hormonal imbalance is appropriate.

---

Opinion: A More Thoughtful Era of Aesthetic Practice

GLP-1 therapies are improving metabolic health and reducing cardiovascular risk. That is something to support, not undermine. The facial changes we are observing are physiological responses to rapid weight reduction.

These patients challenge us to practise with restraint. Not every hollow requires filling, and not every shadow needs chasing. In my clinic, the most successful outcomes are subtle and staged. A small amount of structural support combined with collagen stimulation and optimised skincare often restores vitality without altering identity.

Patients do not want to look augmented. They want to look rested and aligned with how they feel. Post-weight-loss faces demand anatomical understanding, careful staging and honest conversation. In many ways, this patient cohort is encouraging a more regenerative and patient-centred model of aesthetic medicine. That, in my view, is a positive evolution for our profession.

References

1. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525-536. doi:10.1016/S2213-8587(15)00482-9.
2. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165. doi:10.1016/j.cmet.2006.01.004.
3. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100. doi:10.2337/diacare.28.5.1092.
4. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892.
5. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
6. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.
7. Jackson SE, Brown J, Llewellyn C, Mytton O, Shahab L. Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain. BMC Med. 2026;24(1):1. doi:10.1186/s12916-025-04528-7.
8. Rohrich RJ, Pessa JE. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg. 2007;119(7):2219-2227. doi:10.1097/01.prs.0000265403.66886.54.
9. Kang S, Fisher GJ, Voorhees JJ. Photoaging and topical tretinoin: therapy, pathogenesis, and prevention. Arch Dermatol. 1997;133(10):1280-1284.